Drugs / Donor-derived Mesenchymal Stromal Cells
Donor-derived Mesenchymal Stromal Cells
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07177677 | Sep 2025 → Dec 2026 expected | autism spectrum disorder | Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT03504241 | Jul 2018 → Sep 2023 | disease related to solid organ transplantation | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06111846 | Dec 2023 → Jul 2025 overdue | autoimmune pulmonary alveolar proteinosis | Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Donor-derived Mesenchymal Stromal Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03504241 ↗ |
| Known as | hBMMSC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07177677 ↗ |
| Known as | human Bone Marrow Mesenchymal Stem Cell | “human Bone Marrow Mesenchymal Stem Cell (hBMMSC)” NCT07177677 ↗ |
| Modality | Cell therapy | “These MSCs are a cellular product derived from bone marrow” NCT03504241 ↗ |
| Route | Intravenous | “hBMMSC intravenous treatment” NCT06111846 ↗ |